A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age

Vaccine

Volumn 35, Issue 30, 2017, Pages 3749-3759

  August, Allison ^a   Glenn, Gregory M ^a   Kpamegan, Eloi ^a   Hickman, Somia P ^a   Jani, Dewal ^a   Lu, Hanxin ^a   Thomas, D Nigel ^a   Wen, Judy ^a   Piedra, Pedro A ^b   Fries, Louis F ^a  

^a NOVAVAX INC   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

anti F immunoglobulin G (IgG); Maternal immunization, transplacental antibody transfer; Neutralizing antibody; Palivizumab competitive antibody; RSV vaccine

Indexed keywords

ALUMINUM; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; PALIVIZUMAB; PLACEBO; RESPIRATORY SYNCYTIAL VIRUS FUSION PARTICLE VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE; F PROTEIN, HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGICAL ADJUVANT; VIRUS ANTIBODY; VIRUS FUSION PROTEIN;

ADJUVANT THERAPY; ADULT; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; CHILL; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INJECTION SITE CONTUSION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MYALGIA; NAUSEA; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRACTICE GUIDELINE; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; THIRD TRIMESTER PREGNANCY; VACCINATION; VACCINE IMMUNOGENICITY; VOMITING; WESTERN BLOTTING; ADOLESCENT; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; GENETICS; IMMUNOLOGY; MULTICENTER STUDY; PREGNANCY COMPLICATION; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOGENICITY, VACCINE; IMMUNOGLOBULIN G; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; VACCINES, VIRUS-LIKE PARTICLE; VIRAL FUSION PROTEINS; YOUNG ADULT;

EID: 85020115094     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.05.045     Document Type: Article

References (36)

1. Nair, H., Nokes, D.J., Gessner, B.D., Dherani, M., Madhi, S.A., Singleton, R.J., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375 (2010), 1545–1555, 10.1016/S0140-6736(10)60206-1.
2. Boyce, T.G., Mellen, B.G., Mitchel, E.F. Jr., Wright, P.F., Griffin, M.R., Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 137 (2000), 865–870, 10.1067/mpd.2000.110531.
3. Stockman, L.J., Curns, A.T., Anderson, L.J., Fischer-Langley, G., Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997–2006. Pediatr Infect Dis J 31 (2012), 5–9, 10.1097/INF.0b013e31822e68e6.
4. Hall, C.B., Weinberg, G.A., Blumkin, A.K., Edwards, K.M., Staat, M.A., Schultz, A.F., et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics 132 (2013), e341–e348, 10.1542/peds.2013-0303.
5. Hall, C.B., Weinberg, G.A., Iwane, M.K., Blumkin, A.K., Edwards, K.M., Staat, M.A., et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 360 (2009), 588–598, 10.1056/NEJMoa0804877.
6. Swamy, G.K., Heine, R.P., Vaccinations for pregnant women. Obstet Gynecol 125 (2015), 212–226, 10.1097/AOG.0000000000000581.
7. Mutsaerts, E., Madhi, S.A., Cutland, C.L., Jones, S., Hugo, A., Trenor, S., et al. Influenza vaccination of pregnant women protects them over two consecutive influenza seasons in a randomized controlled trial. Expert Rev Vaccines 15 (2016), 1055–1062, 10.1080/14760584.2016.1192473.
8. Nunes, M.C., Aqil, A.R., Omer, S.B., Madhi, S.A., The effects of influenza vaccination during pregnancy on birth outcomes: a systematic review and meta-analysis. Am J Perinatol 33 (2016), 1104–1114, 10.1055/s-0036-1586101.
9. Nunes, M.C., Cutland, C.L., Jones, S., Hugo, A., Madimabe, R., Simoes, E.A., et al. Duration of infant protection against influenza illness conferred by maternal immunization: secondary analysis of a randomized clinical trial. JAMA Pediatr 170 (2016), 840–847, 10.1001/jamapediatrics.2016.0921.
10. Beeler, J.A., van Wyke, Coelingh K., Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 63 (1989), 2941–2950.
11. Swanson, K.A., Settembre, E.C., Shaw, C.A., Dey, A.K., Rappuoli, R., Mandl, C.W., et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A 108 (2011), 9619–9624, 10.1073/pnas.1106536108.
12. Tapia, L.I., Shaw, C.A., Aideyan, L.O., Jewell, A.M., Dawson, B.C., Haq, T.R., et al. Gene sequence variability of the three surface proteins of human respiratory syncytial virus (HRSV) in Texas. PLoS One, 9, 2014, e90786, 10.1371/journal.pone.0090786.
13. Carbonell-Estrany, X., Simoes, E.A., Dagan, R., Hall, C.B., Harris, B., Hultquist, M., et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 125 (2010), e35–e51, 10.1542/peds.2008-1036.
14. Feltes, T.F., Sondheimer, H.M., Tulloh, R.M., Harris, B.S., Jensen, K.M., Losonsky, G.A., et al. A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease. Pediatr Res 70 (2011), 186–191, 10.1038/pr.2011.41110.1203/PDR.0b013e318220a553.
15. Groothuis, J.R., Hoopes, J.M., Hemming, V.G., Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis. Adv Ther 28 (2011), 110–125, 10.1007/s12325-010-0101-y.
16. Smith, G., Raghunandan, R., Wu, Y., Liu, Y., Massare, M., Nathan, M., et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One, 7, 2012, e50852, 10.1371/journal.pone.0050852.
17. Raghunandan, R., Lu, H., Zhou, B., Xabier, M.G., Massare, M.J., Flyer, D.C., et al. An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization. Vaccine 32 (2014), 6485–6492, 10.1016/j.vaccine.2014.09.030.
18. Glenn, G.M., Fries, L.F., Thomas, D.N., Smith, G., Kpamegan, E., Lu, H., et al. A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. J Infect Dis 213 (2016), 411–422, 10.1093/infdis/jiv406.
19. Glenn, G.M., Smith, G., Fries, L., Raghunandan, R., Lu, H., Zhou, B., et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 31 (2013), 524–532, 10.1016/j.vaccine.2012.11.009.
20. Piedra, P.A., Jewell, A.M., Cron, S.G., Atmar, R.L., Glezen, W.P., Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 21 (2003), 3479–3482.
21. Piedra, P.A., Grace, S., Jewell, A., Spinelli, S., Bunting, D., Hogerman, D.A., et al. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J 15 (1996), 23–31.
22. Ammon Avalos, L., Galindo, C., Li, D.K., A systematic review to calculate background miscarriage rates using life table analysis. Birth Defects Res A Clin Mol Teratol 94 (2012), 417–423, 10.1002/bdra.23014.
23. Edwards, D.R., Aldridge, T., Baird, D.D., Funk, M.J., Savitz, D.A., Hartmann, K.E., Periconceptional over-the-counter nonsteroidal anti-inflammatory drug exposure and risk for spontaneous abortion. Obstet Gynecol 120 (2012), 113–122, 10.1097/AOG.0b013e3182595671.
24. Li, D.K., Liu, L., Odouli, R., Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ, 327, 2003, 368, 10.1136/bmj.327.7411.368.
25. Abu Raya, B., Srugo, I., Kessel, A., Peterman, M., Bader, D., Gonen, R., et al. The effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody levels - a prospective study. Vaccine 32 (2014), 5787–5793, 10.1016/j.vaccine.2014.08.038.
26. Eberhardt, C.S., Blanchard-Rohner, G., Lemaitre, B., Boukrid, M., Combescure, C., Othenin-Girard, V., et al. Maternal immunization earlier in pregnancy maximizes antibody transfer and expected infant seropositivity against pertussis. Clin Infect Dis 62 (2016), 829–836, 10.1093/cid/ciw027.
27. Naidu, M.A., Muljadi, R., Davies-Tuck, M.L., Wallace, E.M., Giles, M.L., The optimal gestation for pertussis vaccination during pregnancy: a prospective cohort study. Am J Obstet Gynecol 215:237 (2016), e1–e6, 10.1016/j.ajog.2016.03.002.
28. Wheeler, S.M., Dotters-Katz, S., Heine, R.P., Grotegut, C.A., Swamy, G.K., Maternal effects of respiratory syncytial virus infection during pregnancy. Emerg Infect Dis 21 (2015), 1951–1955, 10.3201/eid2111.150497.
29. Chu, H.Y., Katz, J., Tielsch, J., Khatry, S.K., Shrestha, L., LeClerq, S.C., et al. Clinical presentation and birth outcomes associated with respiratory syncytial virus infection in pregnancy. PLoS One, 11, 2016, e0152015, 10.1371/journal.pone.0152015.
30. Madhi, S.A., Cutland, C.L., Kuwanda, L., Weinberg, A., Hugo, A., Jones, S., et al. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 371 (2014), 918–931, 10.1056/NEJMoa1401480.
31. Benowitz, I., Esposito, D.B., Gracey, K.D., Shapiro, E.D., Vazquez, M., Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants. Clin Infect Dis 51 (2010), 1355–1361, 10.1086/657309.
32. Dabrera, G., Zhao, H., Andrews, N., Begum, F., Green, H., Ellis, J., et al. Effectiveness of seasonal influenza vaccination during pregnancy in preventing influenza infection in infants, England, 2013/14. Euro Surveill, 19, 2014, 20959.
33. Eick, A.A., Uyeki, T.M., Klimov, A., Hall, H., Reid, R., Santosham, M., et al. Maternal influenza vaccination and effect on influenza virus infection in young infants. Arch Pediatr Adolesc Med 165 (2011), 104–111, 10.1001/archpediatrics.2010.192.
34. Poehling, K.A., Szilagyi, P.G., Staat, M.A., Snively, B.M., Payne, D.C., Bridges, C.B., et al. Impact of maternal immunization on influenza hospitalizations in infants. Am J Obstet Gynecol 204 (2011), S141–S148, 10.1016/j.ajog.2011.02.042.
35. Regan, A.K., Klerk, N., Moore, H.C., Omer, S.B., Shellam, G., Effler, P.V., Effectiveness of seasonal trivalent influenza vaccination against hospital-attended acute respiratory infections in pregnant women: A retrospective cohort study. Vaccine 34 (2016), 3649–3656, 10.1016/j.vaccine.2016.05.032.
36. Zaman, K., Roy, E., Arifeen, S.E., Rahman, M., Raqib, R., Wilson, E., et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 359 (2008), 1555–1564, 10.1056/NEJMoa0708630.